{"id":746047,"date":"2019-05-07T05:45:00","date_gmt":"2019-05-07T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/"},"modified":"2025-05-12T08:58:09","modified_gmt":"2025-05-12T12:58:09","slug":"mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/","title":{"rendered":"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia"},"content":{"rendered":"<p class=\"bwalignc\">       First Randomized Controlled Polysomnography Trial of Insomnia        Medication in Alzheimer\u2019s Disease Dementia Population     <\/p>\n<p class=\"bwalignc\">       Data to be Filed with FDA for Potential Inclusion in BELSOMRA        Prescribing Information     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of results of a Phase 3 trial<br \/>\n      evaluating the efficacy and safety of BELSOMRA<sup>\u00ae<\/sup> (suvorexant)<br \/>\n      C-IV for the treatment of insomnia in people with mild-to-moderate<br \/>\n      Alzheimer\u2019s disease dementia.\n    <\/p>\n<p>\n      This is the first dedicated Phase 3 polysomnography study of an insomnia<br \/>\n      medication in people with mild-to-moderate Alzheimer\u2019s disease dementia,<br \/>\n      and in the trial, BELSOMRA met its primary and secondary efficacy<br \/>\n      endpoints. For the primary endpoint, 4-weeks of treatment with BELSOMRA<br \/>\n      improved mean total sleep time (TST) by 28.2 minutes versus placebo<br \/>\n      (n=135 vs. n=139, respectively; [95% CI:11.1,45.2], p&lt;0.005). This<br \/>\n      corresponded to a mean increase from baseline of 73.4 minutes with<br \/>\n      BELSOMRA [95% CI: 61.3, 85.5] and a mean increase from baseline of 45.2<br \/>\n      minutes with placebo [95% CI: 33.3, 57.2]. Adverse events were reported<br \/>\n      in 22.5% of patients receiving BELSOMRA compared to 16.1% of those<br \/>\n      receiving placebo. The results are being presented at the 2019 American<br \/>\n      Academy of Neurology Annual Meeting, held May 4-10 in Philadelphia, PA.\n    <\/p>\n<p>\n      \u201cInsomnia and other sleep disturbances are more common in people with<br \/>\n      Alzheimer\u2019s disease dementia, but evidence for the efficacy and safety<br \/>\n      of sleep medications in this population remains limited,\u201d said Dr. W.<br \/>\n      Joseph Herring, associate vice president, Global Clinical Research,<br \/>\n      Neuroscience, Merck Research Laboratories. \u201cWe are encouraged by the<br \/>\n      efficacy and safety results of BELSOMRA in those living with Alzheimer\u2019s<br \/>\n      disease dementia. Merck plans to file these data with the U.S. Food and<br \/>\n      Drug Administration for potential inclusion into the BELSOMRA<br \/>\n      prescribing information.\u201d\n    <\/p>\n<p>\n      BELSOMRA (suvorexant) C-IV 5 mg, 10 mg, 15 mg and 20 mg tablets are<br \/>\n      currently approved in the United States for treatment of insomnia<br \/>\n      characterized by difficulties with sleep onset and sleep maintenance.\n    <\/p>\n<p>\n      <b>Study Design<\/b>\n    <\/p>\n<p>\n      The Phase 3 randomized, double-blind, clinical trial evaluated the<br \/>\n      efficacy and safety of BELSOMRA (suvorexant) 10 mg, which could be<br \/>\n      increased to a 20 mg dose based on clinical response (77% of patients<br \/>\n      treated with BELSOMRA increased their dose from 10 mg to 20 mg after the<br \/>\n      second week of study) or matching placebo in participants with<br \/>\n      mild-to-moderate Alzheimer\u2019s disease dementia (a score of 12-26 on the<br \/>\n      Mini Mental State Examination) and insomnia (mean total sleep time less<br \/>\n      than 6 hours). Sleep was measured by overnight polysomnography in a<br \/>\n      sleep laboratory. The trial consisted of a 3-week screening period with<br \/>\n      a 2-week single blind placebo run in followed by a 4-week double blind<br \/>\n      randomized treatment period. Overnight polysomnography in a sleep<br \/>\n      laboratory was performed during a visit 14 days prior to randomization,<br \/>\n      at a baseline visit 7 days prior to randomization and following the<br \/>\n      4-week double-blind treatment period. The primary endpoint of the study<br \/>\n      was change-from-baseline in polysomnography-measured mean TST in minutes<br \/>\n      (higher score indicating improved sleep) at Week 4. The secondary<br \/>\n      efficacy endpoint was mean wake after persistent sleep onset (WASO)<br \/>\n      measured in minutes and defined as the total wake time over the PSG<br \/>\n      recording period after the first period of continuous sleep lasting at<br \/>\n      least 10 minutes (lower score corresponds to better sleep). Additional<br \/>\n      exploratory measures included physician-assessed Clinician Global<br \/>\n      Impression of Severity (CGI-S) of insomnia and a caregiver-reported<br \/>\n      participant subjective Sleep Quality Rating (sSQR).\n    <\/p>\n<p>\n      <b>Study Results<\/b>\n    <\/p>\n<p>\n      Of those participants completing the trial (BELSOMRA n=136; placebo<br \/>\n      n=141), mean (SD) baseline TST was 278 (77) minutes for those receiving<br \/>\n      BELSOMRA and 274 (84) minutes for placebo. Measurement at Week 4 showed<br \/>\n      an increase in TST in the BELSOMRA group compared with placebo<br \/>\n      (model-based least squares mean change-from-baseline in TST: BELSOMRA<br \/>\n      73.4 minutes, placebo 45.2 minutes; difference = 28.2 minutes [95%<br \/>\n      CI:11,45]; p&lt;0.01).\n    <\/p>\n<p>\n      The secondary efficacy endpoint measurement at Week 4 showed an<br \/>\n      improvement in WASO in the BELSOMRA group compared with placebo<br \/>\n      (model-based least squares mean change-from-baseline in WASO: BELSOMRA<br \/>\n      -41.8 minutes, placebo -32.5 minutes; difference = 15.7 minutes [95%<br \/>\n      CI:-28.1,-3.3]; p=0.01).\n    <\/p>\n<p>\n      Safety was assessed by adverse event reports, laboratory analyses,<br \/>\n      electrocardiograms and physical examinations performed as stated in the<br \/>\n      protocol. Adverse events were recorded in 22.5% (n=32\/142) of patients<br \/>\n      in the BELSOMRA group and 16.1% (n=23\/143) in the placebo group. One<br \/>\n      patient in each group discontinued treatment due to an adverse event.<br \/>\n      The most common recorded adverse event was somnolence (drowsiness),<br \/>\n      which was reported in 4.2% (n=6) of patients in the BELSOMRA-treated<br \/>\n      group and 1.4% (n=2) of placebo-treated patients. Somnolence was<br \/>\n      recorded as mild-to-moderate severity. Other adverse events included:<br \/>\n      headache (n=5 on BELSOMRA vs. n=6 on placebo), dry mouth (n=3 vs. n=1)<br \/>\n      and falls (n=3 vs. n=0).\n    <\/p>\n<p>\n      <b>Insomnia and Alzheimer\u2019s Disease<\/b>\n    <\/p>\n<p>\n      Findings indicate that insomnia affects up to 45% of people living with<br \/>\n      Alzheimer\u2019s disease.\n    <\/p>\n<p>\n      Many factors contribute to insomnia, which evidence suggests includes<br \/>\n      when wake-promoting signaling overrides sleep-promoting signaling in the<br \/>\n      brain. There are many neurotransmitters in the brain that regulate<br \/>\n      wakefulness, including the orexin signaling system. Elevated orexin<br \/>\n      levels in cerebral spinal fluid are found in those living with<br \/>\n      Alzheimer\u2019s disease.\n    <\/p>\n<p>\n      Changes occurring in the brain tissue of people with Alzheimer\u2019s disease<br \/>\n      are associated with the loss of mental abilities and are also believed<br \/>\n      to cause disruptions in the sleep\/wake cycle resulting in sleep<br \/>\n      problems. Many people with Alzheimer\u2019s disease wake up more often and<br \/>\n      stay awake longer than those without the disease, which may lead to<br \/>\n      significant shifts in sleep\/wake patterns.\n    <\/p>\n<p>\n      <b>About BELSOMRA (suvorexant)<\/b>\n    <\/p>\n<p>\n      BELSOMRA (suvorexant) is a first-in-class oral, highly selective<br \/>\n      antagonist for orexin receptors. Orexin is a neurotransmitter found in a<br \/>\n      specific part of the brain that can help keep a person awake. The<br \/>\n      mechanism by which BELSOMRA exerts its therapeutic effect is presumed to<br \/>\n      be through antagonism of orexin receptors.\n    <\/p>\n<p>\n      <b>Indication for BELSOMRA (suvorexant)<\/b>\n    <\/p>\n<p>\n      BELSOMRA is indicated for the treatment of insomnia characterized by<br \/>\n      difficulties with sleep onset and\/or sleep maintenance.\n    <\/p>\n<p>\n      <b>Select Safety Information about BELSOMRA<\/b>\n    <\/p>\n<p>\n      BELSOMRA is contraindicated in patients with narcolepsy.\n    <\/p>\n<p>\n      BELSOMRA contains suvorexant, a Schedule IV controlled substance.\n    <\/p>\n<p>\n      BELSOMRA can impair daytime wakefulness. Central nervous system (CNS)<br \/>\n      depressant effects can last for up to several days after discontinuation.\n    <\/p>\n<p>\n      BELSOMRA can impair driving skills and may increase the risk of falling<br \/>\n      asleep while driving. Caution patients taking BELSOMRA 20 mg against<br \/>\n      next-day driving and other activities requiring full mental alertness.\n    <\/p>\n<p>\n      Coadministration with other CNS depressants increases the risk of CNS<br \/>\n      depression. Patients should be advised not to consume alcohol in<br \/>\n      combination with BELSOMRA due to additive effects. Dosage adjustments of<br \/>\n      BELSOMRA and of other concomitant CNS depressants may be necessary when<br \/>\n      administered together because of potentially additive effects. The use<br \/>\n      of BELSOMRA (suvorexant) with other drugs to treat insomnia is not<br \/>\n      recommended.\n    <\/p>\n<p>\n      The risk of next-day impairment, including impaired driving, is<br \/>\n      increased if BELSOMRA is taken with less than a full night of sleep<br \/>\n      remaining, if a higher than recommended dose is taken, if<br \/>\n      co-administered with other CNS depressants, or if co-administered with<br \/>\n      other drugs that increase blood levels of BELSOMRA. Patients should be<br \/>\n      cautioned against driving and other activities requiring complete mental<br \/>\n      alertness if taken in these circumstances.\n    <\/p>\n<p>\n      Reevaluate patients for comorbid conditions if insomnia persists after 7<br \/>\n      to 10 days of treatment.\n    <\/p>\n<p>\n      A variety of cognitive and behavioral changes (e.g., amnesia, anxiety,<br \/>\n      hallucinations, and other neuropsychiatric symptoms) have been reported<br \/>\n      with the use of hypnotics such as BELSOMRA. Complex behaviors such as<br \/>\n      &#8220;sleep-driving&#8221; (i.e., driving while not fully awake after taking a<br \/>\n      hypnotic) and other complex behaviors (e.g., preparing and eating food,<br \/>\n      making phone calls, or having sex), with amnesia for the event, have<br \/>\n      been reported in association with the use of hypnotics. Discontinuation<br \/>\n      of BELSOMRA should be strongly considered for these patients. The use of<br \/>\n      alcohol and other CNS depressants may increase the risk of such<br \/>\n      behaviors. These events can occur in hypnotic-na\u00efve as well as<br \/>\n      hypnotic-experienced persons. Discontinuation of BELSOMRA should be<br \/>\n      strongly considered for patients who report any complex sleep behavior.\n    <\/p>\n<p>\n      In clinical studies, a dose-dependent increase in suicidal ideation was<br \/>\n      observed in patients taking BELSOMRA, as assessed by questionnaire.<br \/>\n      Immediately evaluate patients with suicidal ideation or any new onset<br \/>\n      behavioral changes. Suicidal tendencies may be present and intentional<br \/>\n      overdose is more common in this group of patients. Intentional overdose<br \/>\n      is more common in this group of patients; therefore, the lowest number<br \/>\n      of tablets that is feasible should be prescribed for the patient at any<br \/>\n      one time.\n    <\/p>\n<p>\n      The effect of BELSOMRA on respiratory function should be considered.\n    <\/p>\n<p>\n      Sleep paralysis, hypnagogic\/hypnopompic hallucinations, and<br \/>\n      cataplexy-like symptoms can occur. The risk of cataplexy-like symptoms<br \/>\n      increases with the dose of BELSOMRA.\n    <\/p>\n<p>\n      BELSOMRA is not recommended for patients with severe hepatic impairment<br \/>\n      or those taking a strong CYP3A inhibitor.\n    <\/p>\n<p>\n      In clinical studies, the most common adverse reaction (reported in 5% or<br \/>\n      more of patients treated with 15 mg or 20 mg of BELSOMRA and at least<br \/>\n      twice the placebo rate) was somnolence (BELSOMRA 7%, placebo 3%).\n    <\/p>\n<p>\n      The recommended dose of BELSOMRA is 5 mg in patients receiving moderate<br \/>\n      CYP3A inhibitors.\n    <\/p>\n<p>\n      Digoxin levels should be monitored, as slight increases were seen with<br \/>\n      coadministration of BELSOMRA (suvorexant).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and<br \/>\n      connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"https:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a>&nbsp;and<br \/>\n      <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties.&nbsp;There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful.&nbsp;If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s&nbsp;2018&nbsp;Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a><br \/>\n<span class=\"bwuline\">)<\/span>.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for BELSOMRA (suvorexant) at <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/b\/belsomra\/belsomra_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/b\/belsomra\/belsomra_pi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <b>Please see the Medication Guide for BELSOMRA (suvorexant) at <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/b\/belsomra\/belsomra_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/b\/belsomra\/belsomra_mg.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pam Eisele<br \/>(267) 305-3558<\/p>\n<p>Claire Gillespie<br \/>(267)        305-0932<\/p>\n<p>Investors:<br \/>Teri Loxam<br \/>(908) 740-1986<\/p>\n<p>Michael        DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA \u00ae (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer\u2019s disease dementia. This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer\u2019s disease dementia, and in the trial, BELSOMRA met its primary and secondary efficacy endpoints. For the primary endpoint, 4-weeks of treatment with BELSOMRA improved mean total sleep time (TST) by 28.2 minutes versus placebo (n=135 vs. n=139, respectively; [95% CI:11.1,45.2], p&lt;0.005). This corresponded to a mean increase from baseline of 73.4 minutes with BELSOMRA [95% CI: 61.3, 85.5] and a mean increase from baseline of 45.2 minutes with placebo [95% CI: 33.3, 57.2]. Adverse events were reported in 22.5% of patients receiving BELSOMRA compared to 16.1% of those<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-746047","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA \u00ae (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer\u2019s disease dementia. This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer\u2019s disease dementia, and in the trial, BELSOMRA met its primary and secondary efficacy endpoints. For the primary endpoint, 4-weeks of treatment with BELSOMRA improved mean total sleep time (TST) by 28.2 minutes versus placebo (n=135 vs. n=139, respectively; [95% CI:11.1,45.2], p&lt;0.005). This corresponded to a mean increase from baseline of 73.4 minutes with BELSOMRA [95% CI: 61.3, 85.5] and a mean increase from baseline of 45.2 minutes with placebo [95% CI: 33.3, 57.2]. Adverse events were reported in 22.5% of patients receiving BELSOMRA compared to 16.1% of those\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/\",\"name\":\"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-05-07T05:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA \u00ae (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer\u2019s disease dementia. This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer\u2019s disease dementia, and in the trial, BELSOMRA met its primary and secondary efficacy endpoints. For the primary endpoint, 4-weeks of treatment with BELSOMRA improved mean total sleep time (TST) by 28.2 minutes versus placebo (n=135 vs. n=139, respectively; [95% CI:11.1,45.2], p&lt;0.005). This corresponded to a mean increase from baseline of 73.4 minutes with BELSOMRA [95% CI: 61.3, 85.5] and a mean increase from baseline of 45.2 minutes with placebo [95% CI: 33.3, 57.2]. Adverse events were reported in 22.5% of patients receiving BELSOMRA compared to 16.1% of those","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:09+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/","name":"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-05-07T05:45:00+00:00","dateModified":"2025-05-12T12:58:09+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s BELSOMRA\u00ae (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer\u2019s Disease Dementia"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4523c81c-0418-49e0-9c1e-bd09ab7cda99","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-BELSOMRA-suvorexant-C-IV-Meets-Primary-Efficacy-Endpoint-in-Phase-3-Trial-for-the-Treatment-of-Insomnia-in-People-with-Mild-to-08PNE.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746047\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746047"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}